Tamoxifen or Cyproterone Acetate in Combination with Buserelin Are Ineffective in Patients with Pancreatic Adenocarcinoma
Clicks: 192
ID: 271926
1993
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
6.3
/100
21 views
21 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Experimental evidence and preliminary clinical data suggest a responsiveness of pancreatic adenocarcinoma to sex hormones and LH-RH agonists. In this study, we investigated the effect of the antiestrogen tamoxifen and the anti-androgen cyproterone acetate in combination with the LH-RH agonist buserelin in 9 patients with unresectable pancreatic ade
| Reference Key |
swarovsky1993oncologytamoxifen
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | B. Swarovsky;M. Wolf;K. Havemann;R. Arnold; |
| Journal | oncology |
| Year | 1993 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.